Last update 07 Jun 2025

Anti-CD19 CAR-T cell therapy(Aikangd Biomedical Technology (Suzhou) Co Ltd)

Overview

Basic Info

Drug Type
CAR-T
Synonyms-
Target
CD19
Action
inhibitors
Mechanism
CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), Immunologic cytotoxicity, T lymphocyte replacements
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases
Active Indication-
Inactive Indication
B-Cell LeukemiaB-Cell Lymphoma
Originator Organization
Icartab Biotechnology Co Ltd.Icartab Biotechnology Co Ltd.
Active Organization-
Inactive Organization
Icartab Biotechnology Co Ltd.Icartab Biotechnology Co Ltd.Xuzhou Medical UniversityXuzhou Medical University
License Organization-
Drug Highest PhasePendingPhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with Anti-CD19 CAR-T cell therapy(Aikangd Biomedical Technology (Suzhou) Co Ltd)
ChiCTR-OIC-17013081
/ RecruitingPhase 1IIT
Clinical study of CAR-T immune cell targeted therapy for recurrent/refractory CD19+ leukemia and lymphoma
NCT02782351
/ Unknown statusPhase 1/2IIT
Humanized CAR-T Therapy for Treatment of Recurrent or Refractory B Cell Malignancy by Targeting CD19
100 Clinical Results associated with Anti-CD19 CAR-T cell therapy(Aikangd Biomedical Technology (Suzhou) Co Ltd)
Login to view more data
100 Translational Medicine associated with Anti-CD19 CAR-T cell therapy(Aikangd Biomedical Technology (Suzhou) Co Ltd)
Login to view more data
100 Patents (Medical) associated with Anti-CD19 CAR-T cell therapy(Aikangd Biomedical Technology (Suzhou) Co Ltd)
Login to view more data
100 Deals associated with Anti-CD19 CAR-T cell therapy(Aikangd Biomedical Technology (Suzhou) Co Ltd)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
B-Cell LeukemiaPhase 2
China
Xuzhou Medical UniversityXuzhou Medical University
01 May 2016
B-Cell LeukemiaPhase 2
China
Icartab Biotechnology Co Ltd.Icartab Biotechnology Co Ltd.
01 May 2016
B-Cell LymphomaPhase 2
China
Icartab Biotechnology Co Ltd.Icartab Biotechnology Co Ltd.
01 May 2016
B-Cell LymphomaPhase 2
China
Xuzhou Medical UniversityXuzhou Medical University
01 May 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free